29.11.2021 08:53:36
|
Biotech Stocks Facing FDA Decision In December 2021
(RTTNews) - Just when everyone thought that the worst of the Covid-19 pandemic may be behind us, the emergence of Omicron, a new coronavirus variant, is causing global concern. Detected first in South Africa on November 24, 2021, Omicron cases have now been reported in at least 15 countries.
Can the Omicron variant evade vaccine immunity? Is the new virus more dangerous than its predecessor, i.e., the Delta virus? All this will be known in the coming days and weeks.
Meanwhile, the month of November saw a number of "firsts" on the regulatory front.
On November 12, the FDA approved PharmaEssentia Corp.'s Besremi injection to treat adults with polycythemia vera. Besremi is the first FDA-approved treatment for polycythemia vera that patients can take regardless of their treatment history, and the first interferon therapy specifically approved for polycythemia vera.
AppliedVR received de novo approval from the FDA on November 16 for its prescription-use medical device named EaseVRx to treat chronic low back pain, becoming the first virtual reality provider to receive FDA de novo approval for a pain indication.
BioMarin's Voxzogo received FDA approval on November 19 to improve growth in children of five years of age and older with achondroplasia, the most common form of dwarfism. On November 23, the FDA approved Takeda Pharmaceuticals' Livtencity, the first and only treatment for adults and pediatric patients with post-transplant cytomegalovirus, refractory to conventional antiviral therapies.
Now, let's take a look at the companies awaiting FDA decision in December.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Amgen Inc.mehr Nachrichten
13.12.24 |
Schwacher Handel in New York: Dow Jones zeigt sich schwächer (finanzen.at) | |
13.12.24 |
Angespannte Stimmung in New York: Dow Jones verbucht mittags Abschläge (finanzen.at) | |
13.12.24 |
Zurückhaltung in New York: Dow Jones notiert zum Handelsstart im Minus (finanzen.at) | |
11.12.24 |
Zuversicht in New York: Dow Jones mit Kursplus (finanzen.at) | |
09.12.24 |
Schwacher Handel in New York: Dow Jones liegt schlussendlich im Minus (finanzen.at) | |
09.12.24 |
Zurückhaltung in New York: Dow Jones am Nachmittag leichter (finanzen.at) | |
09.12.24 |
Dow Jones 30 Industrial-Wert Amgen-Aktie: So viel Gewinn hätte ein Amgen-Investment von vor einem Jahr eingefahren (finanzen.at) | |
06.12.24 |
Aufschläge in New York: Dow Jones zum Handelsstart im Plus (finanzen.at) |
Analysen zu Amgen Inc.mehr Analysen
Aktien in diesem Artikel
Amgen Inc. | 257,40 | -1,64% | |
Aquestive Therapeutics Inc Registered Shs | 3,61 | -2,17% | |
arGEN-X SE (spons. ADRs) | 575,00 | 0,00% | |
Bristol-Myers Squibb Co. | 52,88 | -1,03% | |
Coherus BioSciences Inc | 1,52 | 5,60% | |
Eagle Pharmaceuticals Inc | 3,54 | -4,84% | |
Intra-Cellular Therapies Inc | 78,00 | -1,89% | |
Merck Co. | 97,20 | 0,41% | |
Veru Inc Registered Shs | 0,67 | -3,60% |